Sanofi is selling a 50% stake in its Opella subsidiary, which includes Doliprane, to the American private equity firm CD&R, known for investing in unlisted companies since 1978. With an enterprise value of approximately 16 billion euros, CD&R aims to enhance Opella's growth and establish it as a leader in consumer healthcare. Sanofi will retain about 48% ownership, while Bpifrance is expected to acquire a small stake.
The French government has secured strong guarantees in the sale of a 50% stake in Opella, producer of Doliprane, to American investment fund CD & R, which aims to enhance growth. The agreement includes a €70 million investment in France, job protection, and penalties for production stoppages. Sanofi retains a 48% stake, ensuring continued involvement in Opella's operations.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
